Blaine Hackman focuses his practice on post-grant proceedings before the US Patent and Trademark Office (USPTO), and related patent litigation, prosecution, and counseling. Blaine regularly represents clients in inter partes review (IPR) and post-grant review (PGR) proceedings before the Patent Trial and Appeal Board (PTAB), with an emphasis on biotechnology and pharmaceutical technologies.
In addition to his active post-grant proceedings practice, Blaine works with clients on the full spectrum of their intellectual property needs. He has experience representing pharmaceutical and biotechnology clients in intellectual property litigation (including Hatch-Waxman proceedings) and advising clients on patent issues, including patentability and freedom to operate (FTO) evaluations. He has also prosecuted patents and counseled clients in transactions in a variety of technologies, including small molecule and protein therapies, nanotechnology, diagnostic imaging, and analytical chemistry.
Blaine actively publishes, presents, and provides insights to the media on intellectual property-related issues.